Is There (real) Gender Difference in Prognosis of Ischemic Heart Disease?

From this document you will learn the answers to the following questions:

What percentage of patients with MI have dyspnea?

What is the gender difference in symptoms among patients with MI?

What does menopause Exposure to endogenous estrogens delay in women?

Similar documents
Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Antiplatelet and Antithrombotics From clinical trials to guidelines

Atherosclerosis of the aorta. Artur Evangelista

Anticoagulants in Atrial Fibrillation

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

Main Effect of Screening for Coronary Artery Disease Using CT

Listen to your heart: Good Cardiovascular Health for Life

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

EMR Tutorial Acute Coronary Syndrome

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

Hormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time

GENERAL HEART DISEASE KNOW THE FACTS

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline Genova Novembre 2015

Atrial Fibrillation An update on diagnosis and management

What is a Heart Attack? 1,2,3

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney,

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CBT/OTEP 243 Aspirin Administration for ACS

Ischemic Heart Disease: Angina Pectoris

Efficient Evaluation of Chest Pain

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

Acute Coronary Syndromes Education for Healthcare Providers. Hani Kozman, MD Cardiology Division SUNY Upstate Medical University

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

CARDIAC RISKS OF NON CARDIAC SURGERY

Description of problem Description of proposed amendment Justification for amendment ERG response

ACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc

REFERENCE CODE GDHC443DFR PUBLICATION DATE JULY 2014 EVACETRAPIB (ACUTE CORONARY SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023

Preoperative Laboratory and Diagnostic Studies

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

ECG may be indicated for patients with cardiovascular risk factors

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

For the NXT Investigators

Acute Coronary Syndrome Disease Coverage. Forecast Treatment Epidemiology Marketed Drugs Pipeline

Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC

Neal Rouzier responds to the JAMA article on Men and Testosterone

Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project

FFR CT : Clinical studies

A PATIENT S GUIDE TO SECONDARY PREVENTION IN ACUTE CORONARY SYNDROME (ACS)

Prognostic impact of uric acid in patients with stable coronary artery disease

Clinical Study Synopsis

MEDICAL POLICY No R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

STROKE PREVENTION IN ATRIAL FIBRILLATION

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Demonstrating Meaningful Use Stage 1 Requirements for Eligible Providers Using Certified EMR Technology

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν

Issues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW

REFERENCE CODE GDHC435DFR PUBLICATION DATE JULY 2014 XARELTO (ACUTE CORONARY SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023

Perioperative Cardiac Evaluation

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

Coronary Heart Disease (CHD) Brief

L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001

2002 by the American College of Cardiology and the American Heart Association, Inc.

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Quality Improvement. Quantified. TM. Program Overview July, 2008

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

Ischemia and Infarction

Rivaroxaban for acute coronary syndromes

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

ATRIAL FIBRILLATION: Scope of the Problem. October 2015

ACC/AHA 2009 STEMI Guideline Focused Update and What s New in 2012 Guideline

Adjuvant Therapy for Breast Cancer: Questions and Answers

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH

DATE: 29 August 2012 CONTEXT AND POLICY ISSUES

Stage 1 Meaningful Use for Specialists. NYC REACH Primary Care Information Project NYC Department of Health & Mental Hygiene

SEX INCLUSION in CLINICAL TRIALS

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Endoscopy & ACS. 8/1/2014 Dr. Whang

Transcription:

2013 순환기관련학회춘계통합학술대회 Chonnam Nat. Univ. Hosp. Is There (real) Gender Difference in Prognosis of Ischemic Heart Disease? 전남의대심혈관센터순환기내과 안영근

Underestimated ischemic heart disease in women

Go Red for women Americans nationwide will take women's health to heart by wearing red to show their support for women's heart disease awareness

2011 대한민국사망원인통계 통계청 '2011 사망원인통계 '

What is different? Treatment Genetic effect Hormonal effect Coronary lesions Anticoagulation and antithrombotic Tx Atypical symptoms Female specific risk factors Drug response

1. Gender Differences : Genetic Risk Profiles for CVD Estimate whether the genetic risk profiles of CVD differ between the genders False discovery rate analysis between men and women Primary analysis : FINRISK 92 & 97 case-cohort sets - Time to event analysis for CVD - Genotype-sex interaction analysis for CVD - Association with quantitative CVD risk factors in the subcohort free of disease at baseline - Genotype-sex interaction analysis for quantitative CVD risk factors Silander K, et al. PLOS ONE 2008;3:3615

1. Gender Differences : Genetic Risk Profiles for CVD Estimate whether the genetic risk profiles of CVD differ between the genders Gender-specific association between variants and CVD Genetic risk loci for CVD are more detectable in women, while for men they are more confounded by environmental/lifestyle risk factors. Silander K, et al. PLOS ONE 2008;3:3615

2. Hormonal Differences : Menopause Exposure to endogenous estrogens delays the manifestation of atherosclerotic disease in women Women with an early menopause (<40 years) 2 year lower life expectancy compared with women with a normal or late menopause Young women with endogenous estrogen deficiency 7x increase in coronary artery risk Gouva L. et al. HORMONES 2004;3:171-183

2. Hormonal Differences : Menopause Menopause Body weight Central obesity LDL HDL Body fat distribution change Upregulation of RAS system Increased ischemic heart disease

2. Hormonal Differences : Menopause Sexual hormones: Effects on cardiac and mitochondrial activity after ischemia reperfusion in adult rats. Gender difference Influence of sex hormones on heart and mitochondrial functions, from adult castrated female and male, and intact rats Mitochondria are involved in cell survival and are important targets for estrogen actions. Estrogen receptor has been described in mitochondria of different kinds of cells, such as primary cardiomyocytes. Pavon N, et al. J of Steroid Biochemistry and Molecular Biology. 2012;132:135-146

2. Hormonal Differences : Menopause Sexual hormones: Effects on cardiac and mitochondrial activity after ischemia reperfusion in adult rats. Gender difference Western blot analysis of ER α and ER β from intact and castrated, female and male rats mitochondria Cardiac function were worst in intact males and castrated females as compared with those found in intact females and castrated males. Pavon N, et al. J of Steroid Biochemistry and Molecular Biology. 2012;132:135-146

3. Gender differences in anticoagulation and antithrombotic Tx Platelet Biology and Response to Antiplatelet Therapy in Women Selected outcomes in primary prevention trials of aspirin, by sex Wang TY, et al. JACC 2012;59:891-900 Wang, et al. JACC 2012;59:891-900

3. Gender differences in anticoagulation and antithrombotic Tx Platelet Biology and Response to Antiplatelet Therapy in Women Major bleeding by sex and GPI dosing Women respond differently from men to antithrombotic therapies showing a greater propensity for bleeding, even c/ appropriate dosing, and differential benefit in terms of prevention of ischemic events. Wang TY, et al. JACC 2012;59:891-900

5. Female-specific risk factors Polycystic ovary disease Hypertensive disease in pregnancy Gestational diabetes

여성은이렇게많은색을구분할수있습니다

6. Gender Differences in Symptoms Presenting symptoms among patients with documented MI without chest pain 682 men 344 women p value Presyncope 144 (21%) 76 (22%) 0.75 Dyspnea 282 (41%) 144 (42%) 0.89 Palpitation 29 (4.3%) 21 (6.1%) 0.22 Jaw pain 27 (4.0%) 36 (10%) <0.001 Nausea or vomiting 154 (23%) 111 (32%) 0.001 Diaphoresis 203 (30%) 83 (24%) 0.07 Women with ACS more likely to have atypical symptom Sometimes misdiagnosed, delayed treatment Heart 2009;95:20 26.

6. Gender Differences in Symptoms Gender Differences in Symptoms During 60-Second Balloon Occlusion of the Coronary Artery Tamura A, et al. Am J Cardiol. 2013

6. Gender Differences in Symptoms Incidence of chest pain and non-chest pain symptoms during 60-second balloon inflation Non-chest pain symptoms during the 60-second balloon occlusion of the coronary artery were more common in women than in men, supporting the presence of the gender difference in myocardial ischemic symptoms Tamura A, et al. Am J Cardiol. 2013

7. Gender Differences in coronary lesion Gender and the Extent of Coronary Atherosclerosis, Plaque Composition, and Clinical Outcomes in ACS Baseline QCA Characteristics of NC Lesions According to Sex Lansky AJ, et al. J Am Coll Cardiol Img 2012;5:S62-72

7. Gender Differences in coronary lesion Baseline IVUS Characteristics of Coronary Tree According to Sex Women have less extensive coronary artery disease by angiographic and IVUS measures, and that lesions in women compared with men have less plaque rupture, less necrotic core and calcium, similar plaque burden, and smaller lumens. TCFA was a stronger marker of plaque vulnerability Lansky AJ, et al. J Am Coll Cardiol Img 2012;5:S62-72

7. Gender Differences in coronary lesion Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study Distribution of the four VH-IVUS plaque components in the non-culprit lesions according to gender Ruiz-García J, et al. Eurointervention 2012;8:929-938

7. Gender Differences in coronary lesion Distribution of the four VH-IVUS plaque components in the non-culprit lesions according to gender Gender-specific differences in the extent and composition of coronary plaque are present in patients <65 years (but not 65 years) of age: Man had a greater number of fibroatheromas and NCLs per patient with larger plaque volumes, and fewer fibrotic plaques than women in the same age group. Ruiz-García J, et al. Eurointervention 2012;8:929-938

8. Gender Differences in treatment 2007 ACC/AHA Guideline - UA/NSTEMI (For women) Women with UA/NSTEMI should be managed with the same pharmacological therapy as men both in the hospital and for secondary prevention Recommended indications for noninvasive testing in women with UA/NSTEMI are similar to those for men For women with high risk features, recommendations for invasive strategy are similar to those of men For women with low risk features, a conservative strategy is recommended

8. Gender Differences in treatment Use of medical treatment by gender in the CRUSADE study Capodanno D et al. Thromb Haemost 2010;104:471-484

8. Gender Differences in treatment Do men benefit more than women from an interventional strategy in patients with UA or NSTEMI? An early intervention strategy resulted in a beneficial effect in men which was not seen in women although caution is needed in interpretation. Eur Heart J. 2004;25:1641 50

8. Gender Differences in treatment Gender differences of success rate of PCI and short term cardiac events Initial therapeutic strategy in acute STEMI: More conservative in female KAMIR data. Int J Cardiol. 2008;130:227-234

8. Gender Differences in treatment Gender differences of success rate of PCI and short term cardiac events The rate of PCI during hospitalization: Lower in female KAMIR data. Int J Cardiol. 2008;130:227-234

8. Gender Differences in treatment One month clinical follow-up for the development of MACEs One month MACE was higher in females than males in Korea. KAMIR data. Int J Cardiol. 2008;130:227-234

Is There (real) Gender Difference in Prognosis of IHD? Adjustment Model Haxard Rations(95% Cl) p c-stat Unadjusted 2.08(1.86-2.34) <0.001 0.58 Adjustment Model 1' : age only 1.28(1.13-1.44) <0.001 0.70 Adjustment Model 2'' : age and medical history 1.09(0.96-1.24) 0.376 0.77 Adjustment Model 3 : age, medical history, and hemodynamic 1.02(0.90-1.16) 0.76 0.81 Adjustment Model 4 : age, medical history, hemodynamic and clinical performance 1.02(0.89-1.17) 0.798 0.82 Propensity Score-Matched Model 1.00(0.84-1.19) 0.984 0.5 1 2 4 Women at increased risk KAMIR/KorMI data. Am J Cardiol. 2012;109:787 793

Is There (real) Gender Difference in Prognosis of IHD? Although women have a higher in-hospital mortality than men, female gender itself is not an independent risk factor for in-hospital mortality KAMIR data. Clin Cardiol. 2010;33: E1 E6

Conclusion There seems to be gender difference in IHD between men and women. Differences in prognosis between women and men with IHD are currently under attention. Still little is known about the prognostic implications of differences. Gender-based interpretation is needed to improve therapeutic efficacy and outcomes in women. Age, years

경청해주셔서감사합니다. Chonnam Nat. Univ. Hosp. 11th Gwangju Interventional Cardiology Symposium (Live demonstration) Date: 7 th - 8 th June, 2013 Venue: Myung-Hak Hall, Chonnam National University Medical School, Gwangju